Sign In
Buy DTIL
$6.04
-0.280 (-4.43%)
At Close: Jun 03, 2026
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUSÂ platform to develop in vivo gene edit
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences (DTIL) Reports Q1 Loss, Tops Revenue Estimates
09:26am, Tuesday, 05'th May 2026
Precision BioSciences (DTIL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to a loss of $2.21 per share a year ago.
Precision BioSciences Reports First Quarter 2026 Financial Results and Provides Business Update
07:01am, Tuesday, 05'th May 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences to Report First Quarter 2026 Financial Results on May 5, 2026
07:01am, Thursday, 30'th Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences Activates First Clinical Trial Site and Begins Patient Enrollment in Phase 1/2 FUNCTION-DMD Study
07:01am, Wednesday, 29'th Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences Announces Oral Presentation at the American Society of Gene and Cell Therapy (ASGCT) 2026 Annual Meeting
07:01am, Tuesday, 28'th Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07:01am, Friday, 24'th Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
05:11pm, Wednesday, 15'th Apr 2026
Precision BioSciences, Inc. (DTIL) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Precision BioSciences Expands ELIMINATE-B Trial Following Clinical Trial Application Approval in Two European Countries
07:01am, Wednesday, 15'th Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
Should You Buy Precision BioSciences (DTIL) After Golden Cross?
10:57am, Tuesday, 14'th Apr 2026
Precision BioSciences, Inc. (DTIL) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, DTIL's 50-day simple moving average broke out abo
Precision BioSciences to Participate in the 25th Annual Needham Virtual Healthcare Conference
07:01am, Wednesday, 08'th Apr 2026
DURHAM, N.C.--(BUSINESS WIRE)--Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therap
